NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Milacron Holdings Corp. MCRN
The investigation concerns whether Milacron and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Milacron to Hillenbrand, Inc. for $11.80 in cash and 0.1612 shares of Hillenbrand common stock for each share of Milacron common stock. If you are a Milacron shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/milacron-holdings-corp-mcrn-merger-stock-hillenbrand/.
Monotype Imaging Holdings Inc. TYPE
The investigation concerns whether Monotype Imaging and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Monotype Imaging to HGGC for $19.85 per share. If you are a Monotype Imaging shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/monotype-imaging-holdings-inc-type-merger-stock-hggc/.
Genomic Health, Inc. GHDX
The investigation concerns whether Genomic Health and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Genomic Health to Exact Sciences Corp. Under the terms of the deal, Genomic Health stockholders will receive $27.50 in cash and $44.50 in shares of Exact Sciences stock (subject to a 10% collar centered on Exact Sciences' volume-weighted average price for the 45 trading days ended July 26, 2019) for each share of Genomic Health common stock they own. If you are a Genomic Health shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/genomic-health-inc-ghdx-merger-stock-exact-sciences/.
Cambrex Corporation CBM
The investigation concerns whether Cambrex and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Cambrex to an affiliate of the Permira funds for $60.00 per share. If you are a Cambrex shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/cambrex-corporation-cbm-stock-merger-permira-funds/.
On behalf of shareholders of these companies, Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
